Basf Se Corporation

Ciba Specialty Chemicals Corporation

Nissan Chemical Industries Limited

Ratiopharm Gmbh

Basf Se Ludwigshafen

Paul Van Der Schaaf

Martin Szelagiewicz

Fritz Blatter

Roger Prétôt

Thomas Schäfer

Patrice Bujard

Beat Schmidhalter

Andreas Mühlebach

Bernd Lamatsch

Jemima Schmidt

Heinz Wolleb

Annemarie Wolleb

Ulrich Berens

Natalia Chebotareva

Hans Jürg Kirner

Andreas Burkhard

Kai-Uwe Schoening

Claudia Marcolli

Marie-Claire Hermant

Franz Schwarzenbach

Roman Kolly

Martina Schoemer

Jörg Berghausen

Bruno Inderbitzin

Johannes Schäfter

Martina Schömer

Daniel Rehm

Christian Guckel

A filament containing a core material (CM) coated with a layer of shell material (SM), wherein the (CM) contains the components a) to c):

Filaments based on a coated core material

This invention relates to electroluminescent metal complexes of the formula (I) wherein the ring A, represents an optionally substituted aryl group which can optionally contain heteroatoms, represents an optionally substituted nitrogen containing aryl group, which can optionally contain further heteroatoms, or the ring A may be taken with the ring B binding to the ring A to form a ring; represents an acyclic carbene, or a cyclic carbene (ring C), which can optionally contain heteroatoms, represents an optionally substituted aryl group which can optionally contain heteroatoms,

Electroluminescent metal complexes with nucleophilic carbene ligands

The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Crystalline forms of pitavastatin calcium

Disclosed are electroluminescent materials comprising a homopolymer based on recurring structural units of the formula (I) wherein R, RR, R, RR, R, R, Rindependently are H or an organic substituent, where at least one of R, RR, R, RR, R, R, Rcomprises a group Rof the formula &#x2014;(Sp)-[PG']&#x3c; wherein Sp is a divalent organic spacer, PG&#x2032; is a group derived from a polymerizable group, and x10 is 0 or 1, with substituents and spacer as defined in claim. Further disclosed are some novel polymers of this class as well as monomers for their preparation. The homopolymers are advantageously used as a host material in devices further comprising a luminescent component, which is usually selected from phosphorescent metal complexes and fluorescent dopants. 

Dibenzofurane polymers for electroluminiscent devices

This invention relates to electroluminescent metal complexes of the formula (I), wherein the ring A, formula (II), represents an optionally substituted aryl group which can optionally contain heteroatoms, the ring B, formula (III), represents an optionally substituted nitrogen containing aryl group, which can optionally contain further heteroatoms, or the ring A may be taken with the ring B binding to the ring A to form a ring; the group C, formula (IV), represents an acyclic carbene, or a cyclic carbene (ring C), which can optionally contain heteroatoms, the ring D, formula (V), represents an optionally substituted aryl group which can optionally contain heteroatoms, n1 is an integer of 1 to 3, m1 is an integer of 0, 1, or 2, m2 is an integer 0, or 1, Mis a metal with an atomic weight of greater than 40, Lis a monodentate ligand, or a bidentate ligand, Y is &#x2014;C(&#x2550;O)&#x2014;, or &#x2014;C(X), wherein Xis hydrogen, or Calkyl, especially hydrogen, and y is 0, or 1, especially 0; a process for their preparation, electronic devices comprising the metal complexes and their use in electronic devices, especially organic light emitting diodes (OLEDs), as oxygen sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts. 

The present invention relates to a process for the production of porous inorganic materials or a matrix material containing nanoparticles with high uniformity of thickness and/or high effective surface area and to the materials obtainable by this process. By the above-mentioned process materials with a defined thickness in the region of &#xb1;10%, preferably &#xb1;5% of the average thickness are available.

Porous inorganic materials of silcon and oxygen

Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.

Crystalline forms of rosuvastatin calcium salt

Disclosed are electroluminescent metal complexes with triazoles of the formula (I), where n1 is an integer of 1 to 3, m1 and m2 each are an integer 0, 1 or 2, Mis a metal with an atomic weight of greater than 40, Lis a monodentate ligand or a bidentate ligand, Lis a monodentate ligand, Qstands for an organic bridging group completing, together with the bonding carbon atoms of the triazole ring, an annellated, carbocyclic or heterocyclic, non-aromatic ring, which optionally may be substituted, Qrepresents a group of forming a condensed aromatic, or heteroaromatic ring, which can optionally be substituted, as well as new intermediates for the preparation of these complexes, electronic devices comprising the metal complexes and their use in electronic devices, especially organic light emitting diodes (OLEDs), as oxygen sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts. 

Electroluminescent metal complexes with triazoles

The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.

Crystalline forms of Rizatriptan benzoate

The present invention relates to a process for the production of porous inorganic materials or a matrix material containing nanoparticles with high uniformity of thickness and/or high effective surface area and to the materials obtainable by this process. By the abovementioned process materials with a defined thickness in the region of &#xb1;10%, preferably &#xb1;5%, of the average thickness are available.

Process for the production of porous inorganic materials or a matrix material containing nanoparticles

Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Polymorphic forms of sertraline hydrochloride

A novel crystalline form of Fluvastatin sodium hydrate is described, referred to hereinafter as polymorphic Form G. Furthermore, processes for the preparation of this crystalline form and pharmaceutical compositions comprising this crystalline form are reported.

Crystalline form of Fluvastatin sodium

The invention relates to a process for preparing solid particles of a phenolic antioxidant from the IRGANOX series in the form of crystals, particularly IRGANOX 1010 and 1098, the crystal particles obtainable by the process, the further processing of the crystal particles, an aqueous dispersion comprising the phenolic antioxidant, novel crystal modifications of pentaerythritol tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate] (&#x3bc;-form) and N,N'-hexane-1,6diyl-bis[3-(3,5-di-tert-butyl-4-hydroxypheylpropamide)] (&#x3b2;-form) and aqueous dispersion comprising the new crystal modifications.

Growing community of inventors

Hagenthal-le-Haut, France

Paul Van Der Schaaf